Y-Intercept (HK)’s ALX Oncology ALXO Stock Holding History

Y-Intercept (HK)’s Portfolio ALXO Stock Details ALXO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-10,615	Closed	-$79.7K	–	1029
2023 Q2	$79.7K	Buy	+10,615	New	+$69.5K	0.01%	1137

Other funds holding ALXO

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Y-Intercept (HK)'s ALXO Position: Q3 2023 in Review

Y-Intercept (HK) sold out of ALX Oncology (ALXO) in Q3 2023, closing a stake of 10,615 shares — an estimated $79.7K sold.

Y-Intercept (HK) first reported a position in ALXO in Q2 2023 and held it in 1 quarter. The position peaked at $79.7K in Q2 2023. 76 funds tracked by Wall St. Rank hold ALXO as of Q3 2023.

Y-Intercept (HK) reported no remaining ALX Oncology position as of Q3 2023 after selling out during the quarter.
Y-Intercept (HK) sold 10,615 ALX Oncology shares in Q3 2023, an estimated $79.7K.
Y-Intercept (HK) first reported a position in ALX Oncology in Q2 2023 and held it in 1 quarter.
Y-Intercept (HK)'s ALX Oncology position peaked at $79.7K in Q2 2023.
76 funds tracked by Wall St. Rank held ALX Oncology as of Q3 2023.

Based on Y-Intercept (HK)'s 13F filing for Q3 2023, filed 14 Nov 2023.